1990-2021年全球负担和医疗不良影响趋势:来自《2021年全球疾病负担研究》的分析。

IF 4.8 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Frontiers in Pharmacology Pub Date : 2025-09-12 eCollection Date: 2025-01-01 DOI:10.3389/fphar.2025.1655864
Keqing Zhang, Yuhai Gao, Yunfei Lu
{"title":"1990-2021年全球负担和医疗不良影响趋势:来自《2021年全球疾病负担研究》的分析。","authors":"Keqing Zhang, Yuhai Gao, Yunfei Lu","doi":"10.3389/fphar.2025.1655864","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Adverse effects of medical treatment (AEMT) pose a significant global health concern, yet prior studies have mostly focused on specific adverse events or single countries, leaving the long-term global epidemiological patterns insufficiently characterized. As healthcare utilization grows, it is crucial to comprehensively quantify the global, regional, and national burden of AEMT and to forecast future trends for effective resource allocation and quality improvement.</p><p><strong>Methods: </strong>We utilized data from the Global Burden of Disease (GBD) study 2021. AEMT were defined based on GBD criteria, and incidence, prevalence, deaths, and disability-adjusted life years (DALYs) data were extracted. This study was stratified by age, gender, region and socio-demographic index (SDI), and estimated annual percentage change was used to assess the trends from 1990 to 2021. Based on SDI, we conducted health inequality analysis and used the Bayesian age-period-cohort model to predict the trend changes over the next 15 years.</p><p><strong>Results: </strong>Globally, there were 12,481,276 new cases of AEMT, with 122,330 deaths, resulting in 4,846,981 DALYs loss in 2021. The age-standardized incidence (ASIR) and prevalence rates (ASPR) worldwide were showing an upward trend, especially in high SDI regions. Both age-standardized mortality (ASMR) and DALYs rates (ASDR) showed a gradual decline during the study period, but they still carried a heavy burden in the low SDI regions (2021 ASDR: 3.71 [95% UI: 2.90 to 5.68] per 100,000 persons-year; 2021 ASR for DALYs: 150.37 [95% UI: 109.08 to 215.24] per 100,000 persons-year). Australasia demonstrated the highest ASIR and ASPR, while Western Sub-Saharan Africa showed the highest ASMR and ASDR. Health inequality analyses revealed that both absolute and relative inequalities of DALYs were narrowing. By 2036, it is forecast that ASIR will decrease to 72.33 (19.40-125.27) per 100,000 persons-year, and ASDR will decrease to 40.98 (21.52-60.43) per 100,000 persons-year.</p><p><strong>Conclusion: </strong>This study provided a comprehensive global, regional, and national assessment of the burden and inequality of AEMT over the past three decades, coupled with forecasts to 2036. The findings revealed distinct epidemiological patterns across SDI levels and regions, filling an important knowledge gap and offering evidence to guide healthcare safety strategies, medical education, and surveillance systems to further reduce the burden of AEMT worldwide.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"16 ","pages":"1655864"},"PeriodicalIF":4.8000,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12464418/pdf/","citationCount":"0","resultStr":"{\"title\":\"Global burden and trends of adverse effects of medical treatment, 1990-2021: an analysis from the global burden of disease study 2021.\",\"authors\":\"Keqing Zhang, Yuhai Gao, Yunfei Lu\",\"doi\":\"10.3389/fphar.2025.1655864\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Adverse effects of medical treatment (AEMT) pose a significant global health concern, yet prior studies have mostly focused on specific adverse events or single countries, leaving the long-term global epidemiological patterns insufficiently characterized. As healthcare utilization grows, it is crucial to comprehensively quantify the global, regional, and national burden of AEMT and to forecast future trends for effective resource allocation and quality improvement.</p><p><strong>Methods: </strong>We utilized data from the Global Burden of Disease (GBD) study 2021. AEMT were defined based on GBD criteria, and incidence, prevalence, deaths, and disability-adjusted life years (DALYs) data were extracted. This study was stratified by age, gender, region and socio-demographic index (SDI), and estimated annual percentage change was used to assess the trends from 1990 to 2021. Based on SDI, we conducted health inequality analysis and used the Bayesian age-period-cohort model to predict the trend changes over the next 15 years.</p><p><strong>Results: </strong>Globally, there were 12,481,276 new cases of AEMT, with 122,330 deaths, resulting in 4,846,981 DALYs loss in 2021. The age-standardized incidence (ASIR) and prevalence rates (ASPR) worldwide were showing an upward trend, especially in high SDI regions. Both age-standardized mortality (ASMR) and DALYs rates (ASDR) showed a gradual decline during the study period, but they still carried a heavy burden in the low SDI regions (2021 ASDR: 3.71 [95% UI: 2.90 to 5.68] per 100,000 persons-year; 2021 ASR for DALYs: 150.37 [95% UI: 109.08 to 215.24] per 100,000 persons-year). Australasia demonstrated the highest ASIR and ASPR, while Western Sub-Saharan Africa showed the highest ASMR and ASDR. Health inequality analyses revealed that both absolute and relative inequalities of DALYs were narrowing. By 2036, it is forecast that ASIR will decrease to 72.33 (19.40-125.27) per 100,000 persons-year, and ASDR will decrease to 40.98 (21.52-60.43) per 100,000 persons-year.</p><p><strong>Conclusion: </strong>This study provided a comprehensive global, regional, and national assessment of the burden and inequality of AEMT over the past three decades, coupled with forecasts to 2036. The findings revealed distinct epidemiological patterns across SDI levels and regions, filling an important knowledge gap and offering evidence to guide healthcare safety strategies, medical education, and surveillance systems to further reduce the burden of AEMT worldwide.</p>\",\"PeriodicalId\":12491,\"journal\":{\"name\":\"Frontiers in Pharmacology\",\"volume\":\"16 \",\"pages\":\"1655864\"},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2025-09-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12464418/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/fphar.2025.1655864\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fphar.2025.1655864","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

背景:医疗不良反应(AEMT)是一个重大的全球健康问题,但之前的研究大多集中在特定的不良事件或单个国家,导致长期的全球流行病学模式没有充分表征。随着医疗保健利用率的增长,全面量化全球、地区和国家的AEMT负担,并预测未来趋势,以实现有效的资源分配和质量改进,这一点至关重要。方法:我们使用了2021年全球疾病负担(GBD)研究的数据。根据GBD标准定义AEMT,并提取发病率、患病率、死亡和残疾调整生命年(DALYs)数据。本研究按年龄、性别、地区和社会人口指数(SDI)分层,并使用估计的年百分比变化来评估1990年至2021年的趋势。基于SDI,我们进行了健康不平等分析,并使用贝叶斯年龄-时期-队列模型预测了未来15年的趋势变化。结果:在全球范围内,有12481276例AEMT新发病例,122330例死亡,导致2021年损失4846981例DALYs。全球年龄标准化发病率(ASIR)和患病率(ASPR)呈上升趋势,尤其是在SDI高的地区。在研究期间,年龄标准化死亡率(ASMR)和DALYs率(ASDR)均呈逐渐下降趋势,但在低SDI地区仍负担沉重(2021年ASDR: 3.71 [95% UI: 2.90至5.68]/ 10万人-年;2021年DALYs的ASR: 150.37 [95% UI: 109.08至215.24]/ 10万人-年)。澳大利亚的ASIR和ASDR最高,而撒哈拉以南非洲西部的ASMR和ASDR最高。健康不平等分析显示,残疾调整生活年的绝对不平等和相对不平等都在缩小。预计到2036年,ASIR将降至72.33(19.40-125.27)/ 10万人/年,ASDR将降至40.98(21.52-60.43)/ 10万人/年。结论:本研究对过去30年AEMT的负担和不平等进行了全面的全球、地区和国家评估,并对2036年进行了预测。研究结果揭示了不同SDI水平和地区的不同流行病学模式,填补了重要的知识空白,并为指导卫生保健安全战略、医学教育和监测系统提供了证据,以进一步减轻全球AEMT的负担。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Global burden and trends of adverse effects of medical treatment, 1990-2021: an analysis from the global burden of disease study 2021.

Background: Adverse effects of medical treatment (AEMT) pose a significant global health concern, yet prior studies have mostly focused on specific adverse events or single countries, leaving the long-term global epidemiological patterns insufficiently characterized. As healthcare utilization grows, it is crucial to comprehensively quantify the global, regional, and national burden of AEMT and to forecast future trends for effective resource allocation and quality improvement.

Methods: We utilized data from the Global Burden of Disease (GBD) study 2021. AEMT were defined based on GBD criteria, and incidence, prevalence, deaths, and disability-adjusted life years (DALYs) data were extracted. This study was stratified by age, gender, region and socio-demographic index (SDI), and estimated annual percentage change was used to assess the trends from 1990 to 2021. Based on SDI, we conducted health inequality analysis and used the Bayesian age-period-cohort model to predict the trend changes over the next 15 years.

Results: Globally, there were 12,481,276 new cases of AEMT, with 122,330 deaths, resulting in 4,846,981 DALYs loss in 2021. The age-standardized incidence (ASIR) and prevalence rates (ASPR) worldwide were showing an upward trend, especially in high SDI regions. Both age-standardized mortality (ASMR) and DALYs rates (ASDR) showed a gradual decline during the study period, but they still carried a heavy burden in the low SDI regions (2021 ASDR: 3.71 [95% UI: 2.90 to 5.68] per 100,000 persons-year; 2021 ASR for DALYs: 150.37 [95% UI: 109.08 to 215.24] per 100,000 persons-year). Australasia demonstrated the highest ASIR and ASPR, while Western Sub-Saharan Africa showed the highest ASMR and ASDR. Health inequality analyses revealed that both absolute and relative inequalities of DALYs were narrowing. By 2036, it is forecast that ASIR will decrease to 72.33 (19.40-125.27) per 100,000 persons-year, and ASDR will decrease to 40.98 (21.52-60.43) per 100,000 persons-year.

Conclusion: This study provided a comprehensive global, regional, and national assessment of the burden and inequality of AEMT over the past three decades, coupled with forecasts to 2036. The findings revealed distinct epidemiological patterns across SDI levels and regions, filling an important knowledge gap and offering evidence to guide healthcare safety strategies, medical education, and surveillance systems to further reduce the burden of AEMT worldwide.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Frontiers in Pharmacology
Frontiers in Pharmacology PHARMACOLOGY & PHARMACY-
CiteScore
7.80
自引率
8.90%
发文量
5163
审稿时长
14 weeks
期刊介绍: Frontiers in Pharmacology is a leading journal in its field, publishing rigorously peer-reviewed research across disciplines, including basic and clinical pharmacology, medicinal chemistry, pharmacy and toxicology. Field Chief Editor Heike Wulff at UC Davis is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信